TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol \[2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID\], and to Compare the preference/compliance of BID nebulization to QID use of MDI


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: adherence to guideline; Type: OTHER; Interventions: Other: Implementation educational programme | Intervention Type: OTHER; Name: Implementation educational programme; Assigned to Arm(s): adherence to guideline
B: Intervention Type: DRUG; Name: Formoterol Fumurate inhalation solution 20 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg; Assigned to Arm(s): N/A
C: Arm Label: MF/F MDI 100/10 mcg BID with dose counter; Type: EXPERIMENTAL; Interventions: Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ) | Intervention Type: DRUG; Name: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ); Assigned to Arm(s): MF/F MDI 100/10 mcg BID with dose counter
D: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: COPD evidence based care pathway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COPD evidence based care pathway; Assigned to Arm(s): Pathway

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LEVP2006-4 CHANGE 3 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Use of C1INH-nf (Human) for the Prophylactic Treatment to Prevent HAE Attacks and as Treatment in Acute HAE Attacks
Brief Summary: The study objective was to evaluate the safety and efficacy of prophylactic use of C1INH-nf for the prevention of acute HAE attacks.


Options:
A: Arm Label: Open-label C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): Open-label C1INH-nf
B: Arm Label: Participants with hereditary angioedema (HAE); Type: N/A; Interventions: N/A
C: Arm Label: DX-2930 300 mg every 2 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 300mg/2wk | Arm Label: DX-2930 300 mg every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 300mg/4wk | Arm Label: DX-2930 150 mg every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 150mg/4wk | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DX-2930 - 300mg/2wk; Assigned to Arm(s): DX-2930 300 mg every 2 weeks | Intervention Type: DRUG; Name: DX-2930 - 300mg/4wk; Assigned to Arm(s): DX-2930 300 mg every 4 weeks | Intervention Type: DRUG; Name: DX-2930 - 150mg/4wk; Assigned to Arm(s): DX-2930 150 mg every 4 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BCX7353 110mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 capsules | Arm Label: BCX7353 150mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: BCX7353 capsules; Assigned to Arm(s): BCX7353 110mg once daily | Intervention Type: DRUG; Name: BCX7353 capsules; Assigned to Arm(s): BCX7353 150mg once daily | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluierung Eines Therapiemodells Der Autologen Knochenmark-Transplantation Bei Herzerkrankungen Mit Besonderem Schwerpunkt Der Prüfung Verschiedener Progenitorzellen
Brief Summary: Cell transplantation for treatment of heart failure is a novel field of translational research that offers the perspective of developing curative approaches by regenerating or "rejuvenating" lost and/or diseased myocardium and inducing growth of new blood vessels. Based on the safety and preliminary efficacy testing in previous trials, a stringent efficacy testing will be performed in this study. Sixty patients who had myocardial infarction in the past and now need bypass surgery for ongoing coronary artery disease will undergo either bypass surgery and placebo treatment or bypass surgery and injection of CD133 bone marrow cells directly in the heart muscle. The study will be fully blinded, i.e. neither the patient nor the surgeon knows what substance is injected (placebo or cell product). Patients will be followed for 6 months and various heart function measurements will be performed.


Options:
A: Intervention Type: GENETIC; Name: Cell Therapy - Autologous CD34 Positive Cells; Assigned to Arm(s): N/A
B: Arm Label: Stem Cell Therapy; Type: EXPERIMENTAL; Interventions: Device: Intramyocardial Injection of stem cells via NOGA Mapping | Arm Label: Control, then Stem Cell Therapy; Type: OTHER; Interventions: Other: Control, then Stem Cell Therapy | Intervention Type: DEVICE; Name: Intramyocardial Injection of stem cells via NOGA Mapping; Assigned to Arm(s): Stem Cell Therapy | Intervention Type: OTHER; Name: Control, then Stem Cell Therapy; Assigned to Arm(s): Control, then Stem Cell Therapy
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mesenchymal stromal cell | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline | Intervention Type: BIOLOGICAL; Name: Mesenchymal stromal cell; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Saline; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: Intramyocardial injection of autologous CD133+ marrow cells; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with gemcitabine for pancreatic cancer.

PURPOSE: This randomized phase II trial is studying how well gemcitabine works with or without dalteparin in treating patients with locally advanced or metastatic pancreatic cancer.


Options:
A: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
B: Arm Label: Cohort 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 1: Apixaban, 5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2: Apixaban, 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Cohort 1: Apixaban, 10 mg, Cohort 1: Apixaban, 20 mg, Cohort 1: Apixaban, 5 mg, Cohort 2: Apixaban, 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Placebo, Cohort 2: Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with gemcitabine for pancreatic cancer.

PURPOSE: This randomized phase II trial is studying how well gemcitabine works with or without dalteparin in treating patients with locally advanced or metastatic pancreatic cancer.


Options:
A: Arm Label: Cohort A - Isoquercetin; Type: EXPERIMENTAL; Interventions: Drug: Isoquercetin | Arm Label: Cohort B - Isoquercetin; Type: EXPERIMENTAL; Interventions: Drug: Isoquercetin | Intervention Type: DRUG; Name: Isoquercetin; Assigned to Arm(s): Cohort A - Isoquercetin, Cohort B - Isoquercetin
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B
C: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
D: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with gemcitabine for pancreatic cancer.

PURPOSE: This randomized phase II trial is studying how well gemcitabine works with or without dalteparin in treating patients with locally advanced or metastatic pancreatic cancer.


Options:
A: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B
C: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
D: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with gemcitabine for pancreatic cancer.

PURPOSE: This randomized phase II trial is studying how well gemcitabine works with or without dalteparin in treating patients with locally advanced or metastatic pancreatic cancer.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
B: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
C: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
D: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with gemcitabine for pancreatic cancer.

PURPOSE: This randomized phase II trial is studying how well gemcitabine works with or without dalteparin in treating patients with locally advanced or metastatic pancreatic cancer.


Options:
A: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
D: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Postmarketing Study of Probiotics Medication in Childhood Diarrhea
Brief Summary: Probiotic bacteria inhabit the gastrointestinal tracts of healthy individuals and may improve the health status of patients with digestive disease. The first aim of our study will seek to determine if probiotics medication (Bio-Three) inhibit gastrointestinal infection and reduce its inflammatory response in the intestine. The second aim will explore the bacterial count (microbiology) and subsequent immune response in probiotic inhibition of enterocolitis in children. We try to seek to gain an advanced understanding of probiotics versus pathogenic microorganism and host interactions, and mucosal immune responses to probiotics in the intestine.


Options:
A: Arm Label: Lacidofil; Type: EXPERIMENTAL; Interventions: Drug: Lacidofil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lacidofil; Assigned to Arm(s): Lacidofil
B: Intervention Type: DRUG; Name: Biothree; Assigned to Arm(s): N/A
C: Arm Label: LGG; Type: EXPERIMENTAL; Interventions: Drug: LGG | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: micro-crystalline cellulose | Intervention Type: DRUG; Name: LGG; Assigned to Arm(s): LGG | Intervention Type: DRUG; Name: micro-crystalline cellulose; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: GB (Florestor) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: GRALB | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: GC (placebo) | Intervention Type: DRUG; Name: GB (Florestor); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: GRALB; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: GC (placebo); Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparative Acceptability, Safety, Effects and Expense of Specialized, Integrated, and Interdisciplinary Community Rehabilitation for Stroke Survivors and Their Caregivers
Brief Summary: As the population ages and the number of stroke survivors increases, information is needed to determine the best way of providing home care services for rehabilitation to stroke survivors and their caregivers while containing health care costs. This project will address this area by developing and testing the effects and costs of a collaborative and specialized team approach to stroke rehabilitation by health professionals, in a home care setting, compared to usual home care services. The overall goal of this way of providing home care services is to improve the quality of life and function of stroke survivors and their caregivers and prevent future strokes, which will reduce the overall cost to the health care system.


Options:
A: Arm Label: Interprofessional Team Approach; Type: EXPERIMENTAL; Interventions: Other: Interprofessional Team Approach | Arm Label: Usual Home Care Services; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Interprofessional Team Approach; Assigned to Arm(s): Interprofessional Team Approach
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Clinical Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Pathways; Assigned to Arm(s): 1
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2
D: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparative Acceptability, Safety, Effects and Expense of Specialized, Integrated, and Interdisciplinary Community Rehabilitation for Stroke Survivors and Their Caregivers
Brief Summary: As the population ages and the number of stroke survivors increases, information is needed to determine the best way of providing home care services for rehabilitation to stroke survivors and their caregivers while containing health care costs. This project will address this area by developing and testing the effects and costs of a collaborative and specialized team approach to stroke rehabilitation by health professionals, in a home care setting, compared to usual home care services. The overall goal of this way of providing home care services is to improve the quality of life and function of stroke survivors and their caregivers and prevent future strokes, which will reduce the overall cost to the health care system.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin | Intervention Type: DRUG; Name: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asprin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 2
B: Arm Label: Interprofessional Team Approach; Type: EXPERIMENTAL; Interventions: Other: Interprofessional Team Approach | Arm Label: Usual Home Care Services; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Interprofessional Team Approach; Assigned to Arm(s): Interprofessional Team Approach
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet

Answer: B